Gil M. Labrucherie
2019
In 2019, Gil M. Labrucherie earned a total compensation of $7.5M as Chief Operating Officer and Chief Financial Officer at Nektar Therapeutics, a 31% increase compared to previous year.
Compensation breakdown
| Option Awards | $3,661,047 |
|---|---|
| Salary | $683,325 |
| Stock Awards | $3,131,971 |
| Other | $12,498 |
| Total | $7,488,841 |
Labrucherie received $3.7M in option awards, accounting for 49% of the total pay in 2019.
Labrucherie also received $683.3K in salary, $3.1M in stock awards and $12.5K in other compensation.
Rankings
In 2019, Gil M. Labrucherie's compensation ranked 1,228th out of 13,971 executives tracked by ExecPay. In other words, Labrucherie earned more than 91.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,228 out of 13,971 | 91st |
Division Manufacturing | 424 out of 5,701 | 93rd |
Major group Chemicals And Allied Products | 128 out of 2,200 | 94th |
Industry group Drugs | 102 out of 1,886 | 95th |
Industry Pharmaceutical Preparations | 77 out of 1,398 | 95th |
Source: SEC filing on April 30, 2021.
Labrucherie's colleagues
We found three more compensation records of executives who worked with Gil M. Labrucherie at Nektar Therapeutics in 2019.